221 results
8-K
EX-99.1
DVAX
Dynavax Technologies Corp.
8 May 24
Dynavax Reports First Quarter 2024 Financial Results
4:05pm
immunogenicity of Tdap-1018 through a long-term follow-up study of participants that completed a Phase 1 trial of a booster dose of Tdap-1018 compared … assets
Total current assets
Total non-current assets
Total assets
Liabilities and stockholders’ equity
Total current liabilities
Total long-term liabilities
Stockholders’ equity
Total liabilities and stockholders’ equity
8-K
EX-99.1
DVAX
Dynavax Technologies Corp.
22 Feb 24
Dynavax Reports Fourth Quarter and Full Year 2023 Financial Results
4:05pm
liabilities
Total long-term liabilities
Stockholders’ equity
Total liabilities and stockholders’ equity
8-K
EX-99.2
kbeu4 j58ui8m
8 Jan 24
Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Highlights
9:05am
8-K
EX-99.1
8a8zlu 5haoz
8 Jan 24
Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Highlights
9:05am
8-K
EX-99.1
ito7euya8t wq
2 Nov 23
Dynavax Reports Third Quarter 2023 Financial Results and Raises Full Year Revenue Guidance
4:10pm
8-K
EX-99.1
5p7g16o3ro36egbs
3 Aug 23
Dynavax Reports Second Quarter 2023 Financial Results and Raises Full Year Revenue Guidance
4:11pm
8-K
EX-99.1
jsi5x2 yarpqf
2 May 23
Dynavax Reports First Quarter 2023 Financial Results
4:11pm
8-K
EX-99.1
vk06nfd43g69f6d
3 Nov 22
Dynavax Reports Third Quarter 2022 Financial Results
4:10pm
8-K
EX-99.1
p9otah
4 Aug 22
Dynavax Reports Second Quarter 2022 Financial Results
4:09pm
8-K
EX-99.1
7fj2 3mex9vw44
5 May 22
Dynavax Reports First Quarter 2022 Financial Results
4:04pm